EMBC - Embecta Corp.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Parsippany,
United States
Type: Equity
EMBC price evolution
EMBC
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $246.8 | $243.4 | $167 | $206.4 |
| Inventory | $171.5 | $185.6 | $153.2 | $149.2 |
| Total current assets | $761 | $781.1 | $710 | $719.5 |
| Long term investments | ||||
| Property, plant & equipment | $290.4 | $311.6 | $314.8 | $323 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1285.3 | $1267.5 | $1199.6 | $1217.8 |
| Current liabilities | ||||
| Accounts payable | $91 | $66.8 | $52.6 | $42.1 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $374 | $370.7 | $310.4 | $326.6 |
| Long term debt | $1595.5 | $1621.3 | $1622.6 | $1624 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2023.6 | $2031.2 | $1969.2 | $2011.3 |
| Shareholders' equity | ||||
| Retained earnings | -$498.6 | -$504.2 | -$510 | -$530 |
| Other shareholder equity | -$292.8 | -$306.3 | -$299.9 | -$297.5 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 31 Jan 2024 | 30 Oct 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $246.8 | $160.3 | $22.2 | $151 |
| Inventory | $171.5 | $152.1 | $122.8 | $118 |
| Total current assets | $761 | $749.1 | $664.7 | $292 |
| Long term investments | ||||
| Property, plant & equipment | $290.4 | $323.2 | $307.9 | $455 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1285.3 | $1214.4 | $1086.4 | $788 |
| Current liabilities | ||||
| Accounts payable | $91 | $53.5 | $41.4 | $54 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $374 | $353.5 | $301 | $164 |
| Long term debt | $1595.5 | $1625.4 | $1630.7 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2023.6 | $2036.1 | $1977.8 | $194 |
| Shareholders' equity | ||||
| Retained earnings | -$498.6 | -$541.1 | -$577.1 | |
| Other shareholder equity | -$292.8 | -$309.1 | -$324.9 | $594 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $286.1 | $272.5 | $287.2 | $277.3 |
| Cost of revenue | ||||
| Gross Profit | $173.8 | $190.1 | $185.4 | $185.9 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $118.2 | $108.4 | $146.2 | $138.5 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$21.6 | $12.3 | -$19 | -$5.8 |
| Interest expense | -$29 | -$27.8 | -$27.8 | -$27.7 |
| Net income | ||||
| Net income | $14.6 | $14.7 | $28.9 | $20.1 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Oct 2023 | 30 Oct 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1123.1 | $1120.8 | $1129.5 | $1165 |
| Cost of revenue | ||||
| Gross Profit | $735.2 | $749.9 | $774.9 | $800 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $448 | $525.9 | $364.1 | $308 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$34.1 | $35.3 | $33 | $80 |
| Interest expense | -$112.3 | -$107 | -$46.2 | |
| Net income | ||||
| Net income | $78.3 | $70.4 | $223.6 | $415 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$15.8 | -$15.8 | -$6.1 | -$2.7 |
| Financing activities | ||||
| Dividends paid | -$34.5 | -$25.8 | -$17.2 | -$8.6 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$73.4 | -$36.8 | -$25.3 | -$13.5 |
| Effect of exchange rate | $1.2 | -$1.2 | $0.2 | $1.5 |
| Change in cash and equivalents | -$52.3 | -$44.7 | -$20 | -$27.8 |
| (in millions $) | 30 Oct 2024 | 30 Oct 2023 | 30 Oct 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$15.8 | -$26.5 | -$24 | -$39 |
| Financing activities | ||||
| Dividends paid | -$34.5 | -$34.4 | -$8.6 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$73.4 | -$48.7 | -$48 | -$417 |
| Effect of exchange rate | $1.2 | $3.1 | -$9.3 | |
| Change in cash and equivalents | -$52.3 | -$4.4 | $330.9 | |
News
Fundamentals
| Market cap | $1.12B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 57.71M |
| Revenue | $1.12B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $78.30M |
| Revenue Q/Q | -1.72% |
| Revenue Y/Y | -44.40% |
| P/E ratio | 14.30 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.00 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $1.36 |
|---|---|
| ROA | 6.30% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.03 |
| Quick ratio | 1.58 |